Does the media refer more to TYRA or RYTM?

In the previous week, Tyra Biosciences and Tyra Biosciences both had 3 articles in the media. Rhythm Pharmaceuticals' average media sentiment score of 0.83 beat Tyra Biosciences' score of 0.53 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tyra Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LNTH or TYRA more profitable?

Lantheus has a net margin of 18.05% compared to Tyra Biosciences' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Tyra Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 18.05% 29.32% 15.00% Tyra Biosciences N/A -42.66% -39.79%

Does the media refer more to LNTH or TYRA?

In the previous week, Lantheus had 3 more articles in the media than Tyra Biosciences. MarketBeat recorded 6 mentions for Lantheus and 3 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 0.53 beat Lantheus' score of 0.37 indicating that Tyra Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tyra Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PTCT or TYRA?

In the previous week, PTC Therapeutics had 9 more articles in the media than Tyra Biosciences. MarketBeat recorded 12 mentions for PTC Therapeutics and 3 mentions for Tyra Biosciences. PTC Therapeutics' average media sentiment score of 0.69 beat Tyra Biosciences' score of 0.53 indicating that PTC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tyra Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MIRM or TYRA?

In the previous week, Mirum Pharmaceuticals had 5 more articles in the media than Tyra Biosciences. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 3 mentions for Tyra Biosciences. Mirum Pharmaceuticals' average media sentiment score of 0.71 beat Tyra Biosciences' score of 0.53 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tyra Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is TYRA or CNTA more profitable?

Tyra Biosciences' return on equity of -42.66% beat Centessa Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Tyra Biosciences N/A -42.66% -39.79% Centessa Pharmaceuticals N/A -60.37% -44.17%

Does the media refer more to TYRA or CNTA?

In the previous week, Centessa Pharmaceuticals had 1 more articles in the media than Tyra Biosciences. MarketBeat recorded 4 mentions for Centessa Pharmaceuticals and 3 mentions for Tyra Biosciences. Centessa Pharmaceuticals' average media sentiment score of 0.72 beat Tyra Biosciences' score of 0.53 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tyra Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Centessa Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tyra Biosciences (TYRA) Competitors

$30.37 +0.31 (+1.03%)

Closing price 04:00 PM Eastern

Extended Trading

$30.37 0.00 (0.00%)

As of 05:48 PM Eastern

Compare

TYRA vs. RYTM, LNTH, PTCT, MIRM, and CNTA

Should you buy Tyra Biosciences stock or one of its competitors? MarketBeat compares Tyra Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tyra Biosciences include Rhythm Pharmaceuticals (RYTM), Lantheus (LNTH), PTC Therapeutics (PTCT), Mirum Pharmaceuticals (MIRM), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical products" industry.

How does Tyra Biosciences compare to Rhythm Pharmaceuticals?

Tyra Biosciences (NASDAQ:TYRA) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

In the previous week, Tyra Biosciences and Tyra Biosciences both had 3 articles in the media. Rhythm Pharmaceuticals' average media sentiment score of 0.83 beat Tyra Biosciences' score of 0.53 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tyra Biosciences presently has a consensus target price of $47.00, suggesting a potential upside of 54.76%. Rhythm Pharmaceuticals has a consensus target price of $133.13, suggesting a potential upside of 23.78%. Given Tyra Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Tyra Biosciences is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Tyra Biosciences has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A
Rhythm Pharmaceuticals	$189.76M	38.84	-$196.54M	-$3.13	N/A

Tyra Biosciences has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.91, indicating that its share price is 91% more volatile than the broader market.

84.1% of Tyra Biosciences shares are held by institutional investors. 12.5% of Tyra Biosciences shares are held by insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Tyra Biosciences has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Tyra Biosciences' return on equity of -42.66% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-42.66%	-39.79%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

Summary

Tyra Biosciences beats Rhythm Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Tyra Biosciences compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Tyra Biosciences (NASDAQ:TYRA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

Lantheus has a net margin of 18.05% compared to Tyra Biosciences' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Tyra Biosciences	N/A	-42.66%	-39.79%

Lantheus currently has a consensus target price of $101.86, indicating a potential downside of 2.85%. Tyra Biosciences has a consensus target price of $47.00, indicating a potential upside of 54.76%. Given Tyra Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Tyra Biosciences is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are owned by institutional investors. 1.7% of Lantheus shares are owned by insiders. Comparatively, 12.5% of Tyra Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Lantheus had 3 more articles in the media than Tyra Biosciences. MarketBeat recorded 6 mentions for Lantheus and 3 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 0.53 beat Lantheus' score of 0.37 indicating that Tyra Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tyra Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.43	$233.56M	$4.15	25.27
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A

Lantheus has a beta of -0.03, meaning that its stock price is 103% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market.

Summary

Lantheus beats Tyra Biosciences on 9 of the 16 factors compared between the two stocks.

How does Tyra Biosciences compare to PTC Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and Tyra Biosciences (NASDAQ:TYRA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

84.1% of Tyra Biosciences shares are owned by institutional investors. 5.5% of PTC Therapeutics shares are owned by company insiders. Comparatively, 12.5% of Tyra Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, PTC Therapeutics had 9 more articles in the media than Tyra Biosciences. MarketBeat recorded 12 mentions for PTC Therapeutics and 3 mentions for Tyra Biosciences. PTC Therapeutics' average media sentiment score of 0.69 beat Tyra Biosciences' score of 0.53 indicating that PTC Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tyra Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

PTC Therapeutics has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market.

PTC Therapeutics presently has a consensus price target of $91.36, suggesting a potential upside of 8.23%. Tyra Biosciences has a consensus price target of $47.00, suggesting a potential upside of 54.76%. Given Tyra Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Tyra Biosciences is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.71
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Tyra Biosciences has a net margin of 0.00% compared to PTC Therapeutics' net margin of -22.58%. Tyra Biosciences' return on equity of -42.66% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-22.58%	-362.45%	-6.76%
Tyra Biosciences	N/A	-42.66%	-39.79%

PTC Therapeutics has higher revenue and earnings than Tyra Biosciences. PTC Therapeutics is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	4.05	$682.64M	-$2.33	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A

Summary

Tyra Biosciences beats PTC Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Tyra Biosciences compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Tyra Biosciences (NASDAQ:TYRA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

In the previous week, Mirum Pharmaceuticals had 5 more articles in the media than Tyra Biosciences. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 3 mentions for Tyra Biosciences. Mirum Pharmaceuticals' average media sentiment score of 0.71 beat Tyra Biosciences' score of 0.53 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tyra Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

84.1% of Tyra Biosciences shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 12.5% of Tyra Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Mirum Pharmaceuticals currently has a consensus price target of $139.80, indicating a potential upside of 21.81%. Tyra Biosciences has a consensus price target of $47.00, indicating a potential upside of 54.76%. Given Tyra Biosciences' higher possible upside, analysts clearly believe Tyra Biosciences is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Tyra Biosciences has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Tyra Biosciences	N/A	-42.66%	-39.79%

Mirum Pharmaceuticals has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market.

Mirum Pharmaceuticals has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	13.42	-$23.36M	-$13.61	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A

Summary

Mirum Pharmaceuticals beats Tyra Biosciences on 9 of the 15 factors compared between the two stocks.

How does Tyra Biosciences compare to Centessa Pharmaceuticals?

Tyra Biosciences (NASDAQ:TYRA) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

84.1% of Tyra Biosciences shares are owned by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 12.5% of Tyra Biosciences shares are owned by company insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Tyra Biosciences has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

Tyra Biosciences has higher earnings, but lower revenue than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A
Centessa Pharmaceuticals	$15M	419.94	-$197.53M	-$1.79	N/A

Tyra Biosciences' return on equity of -42.66% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-42.66%	-39.79%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

In the previous week, Centessa Pharmaceuticals had 1 more articles in the media than Tyra Biosciences. MarketBeat recorded 4 mentions for Centessa Pharmaceuticals and 3 mentions for Tyra Biosciences. Centessa Pharmaceuticals' average media sentiment score of 0.72 beat Tyra Biosciences' score of 0.53 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Centessa Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tyra Biosciences currently has a consensus price target of $47.00, suggesting a potential upside of 54.76%. Centessa Pharmaceuticals has a consensus price target of $41.33, suggesting a potential upside of 1.53%. Given Tyra Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Tyra Biosciences is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Summary

Tyra Biosciences beats Centessa Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get Tyra Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TYRA vs. The Competition

Export

Metric	Tyra Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.79B	$3.49B	$6.74B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-13.93	20.50	25.39	23.96
Price / Sales	N/A	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	6.25	8.26	10.76	6.41
Net Income	-$119.95M	$23.91M	$3.56B	$337.14M
7 Day Performance	4.47%	3.05%	1.37%	-0.48%
1 Month Performance	-6.47%	2.40%	0.81%	0.49%
1 Year Performance	211.81%	56.35%	30.53%	28.16%

Tyra Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TYRA Tyra Biosciences	2.5526 of 5 stars	$30.37 +1.0%	$47.00 +54.8%	+209.6%	$1.79B	N/A	N/A	20
RYTM Rhythm Pharmaceuticals	3.3069 of 5 stars	$106.19 +4.7%	$133.13 +25.4%	+70.9%	$6.95B	$189.76M	N/A	140	Insider Trade
LNTH Lantheus	3.3282 of 5 stars	$106.03 -0.2%	$101.86 -3.9%	+31.2%	$6.91B	$1.54B	25.55	1,193	News Coverage
PTCT PTC Therapeutics	2.3192 of 5 stars	$82.13 +1.4%	$91.36 +11.2%	+65.6%	$6.72B	$1.73B	N/A	1,410	Positive News Insider Trade
MIRM Mirum Pharmaceuticals	3.7881 of 5 stars	$111.19 +3.2%	$139.80 +25.7%	+121.1%	$6.57B	$521.31M	N/A	140	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TYRA) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tyra Biosciences (TYRA) Competitors

TYRA vs. RYTM, LNTH, PTCT, MIRM, and CNTA

How does Tyra Biosciences compare to Rhythm Pharmaceuticals?

Summary

How does Tyra Biosciences compare to Lantheus?

Summary

How does Tyra Biosciences compare to PTC Therapeutics?

Summary

How does Tyra Biosciences compare to Mirum Pharmaceuticals?

Summary

How does Tyra Biosciences compare to Centessa Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TYRA vs. The Competition

Tyra Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tyra Biosciences (TYRA) Competitors

TYRA vs. RYTM, LNTH, PTCT, MIRM, and CNTA

How does Tyra Biosciences compare to Rhythm Pharmaceuticals?

Does the media refer more to TYRA or RYTM?

Do analysts rate TYRA or RYTM?

Which has stronger valuation and earnings, TYRA or RYTM?

Which has more risk and volatility, TYRA or RYTM?

Do insiders and institutionals believe in TYRA or RYTM?

Is TYRA or RYTM more profitable?

Summary

How does Tyra Biosciences compare to Lantheus?

Is LNTH or TYRA more profitable?

Do analysts prefer LNTH or TYRA?

Do insiders & institutionals believe in LNTH or TYRA?

Does the media refer more to LNTH or TYRA?

Which has stronger earnings & valuation, LNTH or TYRA?

Which has more volatility & risk, LNTH or TYRA?

Summary

How does Tyra Biosciences compare to PTC Therapeutics?

Do institutionals and insiders hold more shares of PTCT or TYRA?

Does the media refer more to PTCT or TYRA?

Which has more volatility & risk, PTCT or TYRA?

Do analysts rate PTCT or TYRA?

Is PTCT or TYRA more profitable?

Which has better earnings & valuation, PTCT or TYRA?

Summary

How does Tyra Biosciences compare to Mirum Pharmaceuticals?

Does the media favor MIRM or TYRA?

Do institutionals & insiders have more ownership in MIRM or TYRA?

Do analysts rate MIRM or TYRA?

Is MIRM or TYRA more profitable?

Which has more volatility and risk, MIRM or TYRA?

Which has better valuation & earnings, MIRM or TYRA?

Summary

How does Tyra Biosciences compare to Centessa Pharmaceuticals?

Do insiders & institutionals have more ownership in TYRA or CNTA?

Which has more risk & volatility, TYRA or CNTA?

Which has stronger valuation and earnings, TYRA or CNTA?

Is TYRA or CNTA more profitable?

Does the media refer more to TYRA or CNTA?

Do analysts rate TYRA or CNTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TYRA vs. The Competition

Tyra Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools